Scinai Immunotherapeutics Ltd (SCNI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.05M
Last updated: Nov 17, 2026 at 10:54 AM ET
Scinai Immunotherapeutics Ltd (SCNI) Financials: Revenue, Profit and Cash Flow
Scinai Immunotherapeutics reported revenue of $1.31M for the fiscal year ended Dec 31, 2025, up 99.2% from the year before. That year, net income was -$8.31M with a net margin of -633.6%, operating cash flow was -$6.03M and free cash flow was -$6.05M. The quarter ended Sep 30, 2026 had revenue of $1.86M and net income of -$1.97M.
Revenue and Margins
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $1.31M | +99.2% | -202.3% | -575.3% | -633.6% |
| Dec 2024 | $658.00K | N/A | -88.1% | -1312.8% | 728.9% |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
| Dec 2018 | N/A | N/A | N/A | N/A | N/A |
| Dec 2017 | N/A | N/A | N/A | N/A | N/A |
| Dec 2016 | N/A | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.31M | $658.00K | $0 | $0 | $0 | $0 | $0 | N/A | N/A | N/A |
| Cost of revenue | $3.96M | $1.24M | $512.67K | $559.80K | $747.65K | $708.92K | $461.69K | $72.32K | $123.55K | N/A |
| Gross profit | -$2.65M | -$580.00K | -$512.67K | -$559.80K | -$747.65K | -$708.92K | N/A | N/A | N/A | N/A |
| Research and development | $2.37M | $5.53M | $5.21M | $5.76M | $2.62M | $14.42M | $19.88M | $19.27M | $5.58M | $2.44M |
| Operating income | -$7.54M | -$8.64M | -$9.71M | -$11.06M | -$10.79M | -$19.82M | -$22.69M | -$20.61M | -$6.80M | -$3.09M |
| Net income | -$8.31M | $4.80M | -$6.50M | -$5.80M | -$12.38M | -$1.30M | -$31.62M | -$23.46M | -$9.93M | -$2.38M |
| EBITDA | -$6.53M | -$6.99M | -$2.19M | -$5.23M | -$10.32M | -$19.11M | -$22.23M | -$20.54M | -$6.67M | -$2.93M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.86M | $467.90K | $487.67K | $263.64K | $269.00K | $386.50K | $586.00K | $206.00K | $168.00K | $284.00K | $0 | $0 |
| Gross profit | -$601.00K | -$1.27M | -$1.11M | -$1.38M | -$691.00K | -$635.00K | $228.00K | -$167.00K | -$249.00K | -$164.00K | -$157.73K | -$84.91K |
| Operating income | -$1.95M | -$2.18M | -$2.46M | -$2.82M | -$1.89M | -$1.88M | -$1.57M | -$2.26M | -$2.42M | $3.96M | -$1.93M | -$1.85M |
| Net income | -$1.97M | -$2.04M | $3.57M | -$2.05M | -$2.09M | -$2.07M | -$1.56M | -$2.23M | $10.46M | -$2.32M | -$2.16M | -$2.36M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $623.00K by $1.04M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $11.63M | $13.45M | $17.47M | $27.07M | $32.04M | $17.71M | $33.52M | $28.30M | $23.48M | $7.82M |
| Current assets | $2.05M | $2.39M | $5.45M | $14.37M | $17.84M | $3.31M | $21.17M | $20.55M | $21.64M | $6.78M |
| Cash and equivalents | $1.66M | $1.96M | $4.87M | $14.07M | $17.37M | $2.93M | $20.98M | $20.29M | $20.51M | $4.08M |
| Total liabilities | $3.52M | $3.47M | $22.04M | $28.83M | $31.05M | $22.25M | $52.36M | $36.65M | $7.31M | $1.17M |
| Short-term debt | $329.00K | $424.00K | $396.00K | $382.00K | $623.36K | $19.00M | $200.97K | N/A | N/A | N/A |
| Long-term debt | $294.00K | $260.00K | $19.37M | $20.08M | $63.25M | N/A | $123.78M | N/A | N/A | N/A |
| Shareholder equity | $8.10M | $9.98M | -$4.57M | -$1.76M | $982.00K | -$4.54M | -$18.84M | -$8.35M | $16.17M | $6.65M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $15.70M | $17.17M | $17.59M | $11.63M | $11.63M | $11.84M | $11.84M | $13.45M | $12.26M | $14.85M | $17.05M | $17.47M |
| Total liabilities | $4.98M | $5.44M | $5.83M | $3.52M | $3.52M | $3.98M | $3.98M | $3.47M | $2.26M | $22.14M | $22.17M | $22.04M |
| Cash and equivalents | $1.71M | $2.85M | $3.11M | $1.66M | $1.66M | $989.00K | $989.00K | $1.96M | $1.03M | $3.08M | $4.83M | $4.87M |
| Shareholder equity | $10.71M | $11.73M | $11.76M | $8.10M | $8.10M | $7.86M | $7.86M | $9.98M | $10.00M | -$7.28M | -$5.12M | -$4.57M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.03M | -$6.33M | -$9.38M | -$7.26M | -$7.43M | -$21.09M | -$22.31M | -$15.29M | -$2.89M | -$2.51M |
| Capital expenditures | $24.00K | $12.00K | $637.00K | $836.00K | $139.00K | $1.78M | $2.15M | $6.35M | $1.30M | N/A |
| Free cash flow | -$6.05M | -$6.35M | -$10.02M | -$8.10M | -$7.57M | -$22.88M | -$24.47M | -$21.64M | -$4.18M | N/A |
| Investing cash flow | -$24.00K | -$12.00K | -$637.00K | -$836.00K | -$139.00K | -$1.73M | -$2.08M | -$6.27M | $1.94M | -$2.03M |
| Financing cash flow | $5.77M | $3.44M | $1.09M | $6.78M | $21.43M | $3.99M | $24.68M | $22.55M | $17.77M | N/A |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.88M | -$2.50M | -$1.45M | -$1.73M | -$1.53M | -$1.04M | -$1.08M | -$2.04M | -$1.75M | -$1.46M | -$1.23M | -$2.22M |
| Capital expenditures | $115.00K | $112.81K | $3.00K | $6.00K | $3.00K | $9.00K | $0 | $4.00K | $6.01K | $2.00K | $234.00K | $20.00K |
| Free cash flow | -$1.99M | -$2.61M | -$1.46M | -$1.73M | -$1.54M | -$1.05M | -$1.08M | -$2.04M | -$1.76M | -$1.47M | -$1.46M | -$2.24M |
Frequently Asked Questions About SCNI
What is Scinai Immunotherapeutics' annual revenue?
Scinai Immunotherapeutics reported revenue of $1.31M for the fiscal year ended Dec 31, 2025.
How fast is Scinai Immunotherapeutics' revenue growing?
Revenue was up 99.2% for the fiscal year ended Dec 31, 2025 compared with the year before.
Is Scinai Immunotherapeutics profitable?
No. Scinai Immunotherapeutics reported net income of -$8.31M for the fiscal year ended Dec 31, 2025, with a net margin of -633.6%.
How much free cash flow does SCNI generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$6.03M minus capital expenditures of $24.00K produced free cash flow of -$6.05M.
How much debt does Scinai Immunotherapeutics have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $294.00K, short-term debt of $329.00K and cash and equivalents of $1.66M.
SCNI pages: Overview, Earnings, Financials, Competitors